Cutaneous T-cell lymphoma (CTCL) is the most prevalent type of primary cutaneous lymphoma with a complex immunological background. CTCL subtypes illustrate different clinical and histological characteristics. Mycosis fungoides and Sézary syndrome are two major subtypes of CTCL. Both diseases are regarded as T-helper cell type 2 diseases although the underlying pathophysiology is not yet totally understood. The pathogenetic mechanisms of CTCL are complex and a single factor has not yet been identified. Diagnosis can therefore be challenging, requiring an interdisciplinary approach. At present, treatment varies and can include skin-directed therapies such as steroids and phototherapy, and systemic treatments including monoclonal antibodies or chemotherapy.
In recent years, there has been an increased effort in finding novel treatments for the management of this disease. Therefore, this Research Topic aims to shed light on various aspects of pathophysiology to identify new treatment options for the management of CTCL. We welcome the submission of original research and review articles focusing on the immunopathology of Cutaneous T-cell lymphoma. This includes, but is not limited to, the following areas:
• New diagnostic techniques in evaluating CTCL
• Current updates on the pathophysiology of CTCL
• Recent advances in the management of CTCL
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Cutaneous T-cell lymphoma (CTCL) is the most prevalent type of primary cutaneous lymphoma with a complex immunological background. CTCL subtypes illustrate different clinical and histological characteristics. Mycosis fungoides and Sézary syndrome are two major subtypes of CTCL. Both diseases are regarded as T-helper cell type 2 diseases although the underlying pathophysiology is not yet totally understood. The pathogenetic mechanisms of CTCL are complex and a single factor has not yet been identified. Diagnosis can therefore be challenging, requiring an interdisciplinary approach. At present, treatment varies and can include skin-directed therapies such as steroids and phototherapy, and systemic treatments including monoclonal antibodies or chemotherapy.
In recent years, there has been an increased effort in finding novel treatments for the management of this disease. Therefore, this Research Topic aims to shed light on various aspects of pathophysiology to identify new treatment options for the management of CTCL. We welcome the submission of original research and review articles focusing on the immunopathology of Cutaneous T-cell lymphoma. This includes, but is not limited to, the following areas:
• New diagnostic techniques in evaluating CTCL
• Current updates on the pathophysiology of CTCL
• Recent advances in the management of CTCL
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
